Initially characterized as one of several genes belonging to potential 3p21.3 TSG cluster [10–12], recently FUS1 gene enters clinical trials as a gene-based therapy in the form of plasmid DNA encapsulated in cation lipid nanopartciles (REQORSA) in combination with other drugs for patients with non-small cell lung cancer (NSCLC) [13]. The gene discussed is TUSC2; the disease is non-small cell lung carcinoma.